Bioartificial liver support devices: Historical perspectives

ANZ Journal of Surgery

Volumn 73, Issue 9, 2003, Pages 739-748

  Court, Fiona G ^a   Wemyss Holden, Simon A ^a   Dennison, Ashley R ^b   Maddern, Guy J ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b LEICESTER GENERAL HOSPITAL   (United Kingdom)

Author keywords

Filtration; Fulminant hepatic failure; Liver regeneration; Liver resection; Liver support; Liver transplantation

Indexed keywords

ALCOHOLISM; ARTIFICIAL LIVER; BIOARTIFICIAL LIVER SUPPORT SYSTEM; BIOARTIFICIAL ORGAN; BIOENGINEERING; CELL TRANSPLANTATION; CELL TYPE; CELL VIABILITY; CELL VOLUME; CLINICAL TRIAL; CROSS CIRCULATION; CYTOLOGY; DEVICE; EXTRACORPOREAL LIVER ASSIST DEVICE; HEMOFILTRATION; HEMOPERFUSION; HUMAN; INFECTION; LIFE EXPECTANCY; LIVER CELL; LIVER FAILURE; LIVER FUNCTION; LIVER TRANSPLANTATION; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; MODULAR EXTRACORPOREAL LIVER SYSTEM; MORALITY; PLASMAPHERESIS; POSTOPERATIVE COMPLICATION; REVIEW; SURVIVAL;

CELLS, CULTURED; HEPATOCYTES; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; LIVER, ARTIFICIAL; TREATMENT OUTCOME;

EID: 0142012184     PISSN: 14451433     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1445-2197.2003.02741.x     Document Type: Review

References (106)

1. Jauregui HO, Chowdhury NR, Chowdhury JR. Use of mammalian liver cells for artificial liver support. Cell Transplant. 1996; 5: 353-67.
2. Nyberg SL, Peshwa MV, Payne WD, Hu WS, Cerra FB. Evolution of the bioartificial liver: the need for randomized clinical trials. Am. J. Surg. 1993; 166: 512-21.
3. Court FG, Wemyss-Holden SA, Dennison AR, Maddern GJ. The mystery of liver regeneration. Br. J. Surg. 2002; 89: 1089-95.
4. Trey C. The fulminant hepatic failure surveillance study. Brief review of the effects of presumed etiology and age of survival. Can. Med. Assoc. J. 1972; 106: 525-7.
5. Rueff B. Acute hepatic necrosis and fulminant hepatic failure. Gut 1973; 14: 805-15.
6. Scotto J. Liver biopsy and prognosis in acute liver failure. Gut 1973; 14: 927-33.
7. Sussman NL, Gislason GT, Kelly JH. Extracorporeal liver support. Application to fulminant hepatic failure. J. Clin. Gastroenterol. 1994; 18: 320-4.
8. Wolf HK, Michalopoulos GK. Hepatocyte regeneration in acute fulminant and nonfulminant hepatitis: a study of proliferating cell nuclear antigen expression. Hepatology 1992; 15: 707-13.
9. Gerlach JC. Long-term liver cell cultures in bioreactors and possible application for liver support. Cell Biol. Toxicol. 1997; 13: 349-55.
10. Ting PP, Demetriou AA. Clinical experience with artificial liver support systems. Can. J. Gastroenterol. 2000; 14: 79D-84D.
11. Busuttil RW, Colonna JO 2nd, Hiatt JR et al. The first 100 liver transplants at UCLA. Ann. Surg. 1987; 206: 387-402.
12. Takahashi T, Malchesky PS, Nose Y. Artificial liver. State of the art. Dig. Dis. Sci. 1991; 36: 1327-40.
13. Gammal SH, Jones EA. Hepatic encephalopathy. Med. Clin. North Am. 1989; 73: 793-813.
14. Kiley J, Welch HF, Pender JC. Removal of blood ammonia by haemodialysis. Proc. Soc. Exp. Biol. Medical 1956; 91: 489-90.
15. Chang TM. Experimental artificial liver support with emphasis on fulminant hepatic failure: concepts and review. Semin. Liver Dis. 1986; 6: 148-58.
16. Williams R, Ede R, Hughes R. Use of artificial liver support. Int J. Clin. Pharmacol Res. 1985; 5: 381-7.
17. Opolon P, Rapin JR, Huguet C et al. Hepatic failure coma (HFC) treated by polyacrylonitrile membrane (PAN) hemodialysis (HD). Trans. Am. Soc. Artif. Intern. Organs 1976; 22: 701-10.
18. Weston MJ, Mellon PJ, Langley PG et al. Resin column perfusion with whole blood or plasma separated by the continuous flow celltrifuge. Clin. Sci. Mol. Med. 1975; 48: 187-92.
19. Stange J, Hassanein TI, Mehta R, Mitzner SR, Bartlett RH. The molecular adsorbents recycling system as a liver support system based on albumin dialysis: a summary of preclinical investigations, prospective, randomized, controlled clinical trial, and clinical experience from 19 centers. Artif. Organs 2002; 26: 103-10.
20. Dixit V, Chang TM. In vitro and clinical studies of the removal of cortisol, thyroxine, insulin, and thyroid-stimulating hormone by coated charcoal haemoperfusion. Life Support Syst. 1984; 2: 238-44.
21. Kokot F, Pietrek J, Seredynski M. Influence of hemopetfusion on the concentration of beta-methyldigoxin and hormones in plasma. Kidney Int. 1979; 15: 404-10.
22. Winchester JF, Ratcliffe JG, Carlyle E, Kennedy AC. Solute, amino acid, and hormone changes with coated charcoal hemoperfusion in uremia. Kidney Int. 1978; 14: 74-81.
23. Filip K, Maly J, Horky J, Tlustakova M, Kalal J, Vrana M. Bilirubin and bile acids removal by haemoperfusion through synthetic resin 'Persorb'. Czech Med. 1990; 13: 34-7.
24. Konstantin P, Chang J, Otto V, Brunner G. Artificial liver. Artif. Organs 1992; 16: 235-42.
25. Sakagami K, Miyazaki M, Matsuoka J, Shiozaki S, Saito S, Orita K. Artificial liver support for postoperative hepatic failure with anion exchange resin (BR-601). Acta Med. Okayama 1986; 40: 249-55.
26. Jauregui HO, Muller TE. Long-term cultures of adult mammalian hepatocytes in hollow fibers as the cellular component of extracorporeal (hybrid) liver assist devices. Artif. Organs 1992; 16: 209-12.
27. Patzer JF, Mazariegos GV, Lopez R et al. Novel bioartificial liver support system: preclinical evaluation. Ann. N. Y. Acad. Sci. 1999; 875: 340-52.
28. Basile AS, Harrison PM, Hughes RD et al. Relationship between plasma benzodiazepine receptor ligand concentrations and severity of hepatic encephalopathy. Hepatology 1994; 19: 112-21.
29. Nyberg SL, Shatford RA, Hu WS, Payne WD, Cerra FB. Hepatocyte culture systems for artificial liver support: implications for critical care medicine (bioartificial liver support). Crit. Care Med. 1992; 20: 1157-68.
30. Stange J, Mitzner SR, Klammt S et al. Liver support by extracorporeal blood purification: a clinical observation. Liver Transpl. 2000; 6: 603-13.
31. Mitzner S, Stange J, Klammt S, Peszynski P, Schmidt R, Noldge-Schomberg G. Extracorporeal detoxification using the Molecular Adsorbent Recirculating System for critically ill patients with liver failure. J. Am. Soc. Nephrol. 2001; 12: 75-82.
32. Mitzner SR, Stange J, Klammt S et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl. 2000; 6: 277-86.
33. Stange J, Mitzner S, Klammt S et al. New extracorporeal liver support for chronic liver disease complicated by cholestasis -results of a prospective randomized two center trial. J. Hepatol. 2001; 34: 45.
34. Sorkine P, Abraham B, Szold O et al. Role of the molecular adsorbent recycling system (MARS) in the treatment of patients with acute exacerbation of chronic liver failure. Crit. Care Med. 2001; 29: 1332-6.
35. Stange J, Mitzner S, Risler T et al. Molecular adsorbent recycling system (MARS): clinical results of a new membrane-based blood purification system for bioartificial liver support. Artif. Organs 1999; 23: 319-30.
36. Kellersmann R, Gassel HJ, Buhler C, Thiede A, Timmermann W. Application of Molecular Adsorbent Recirculating System (R) in patients with severe liver failure after hepatic resection or transplantation: initial single-centre experiences. Liver 2002; 22: 56-8.
37. Novelli G, Rossi M, Pretagostini R et al. Use of MARS in the treatment of acute liver failure: preliminar monocentric experience. Transplant. Proc. 2001; 33: 1942-4.
38. Awad S, Swaniker F, Magee J, Punch J, Bartlett RH. Results of a phase I trial evaluating a liver support device utilizing albumin dialysis. Surgery 2001; 130: 354-62.
39. Davies E, Hodgson HJ. Artificial livers - what's keeping them? Gut 1995; 36: 168-70.
40. Eiseman B. Treatment of hepatic coma by extracorporeal liver perfusion. Ann. R. Coll. Surg. Engl. 1966; 38: 329-48.
41. Pascher A, Sauer IM, Hammer C, Gerlach JC, Neuhaus P. Extracorporeal liver perfusion as hepatic assist in acute liver failure: a review of world experience. Xenotransplantation 2002; 9: 309-24.
42. Chari RS, Collins BH, Magee JC et al. Brief report: treatment of hepatic failure with ex vivo pig-liver perfusion followed by liver transplantation. N. Engl. J. Med. 1994; 331: 234-7.
43. Stockmann HB, Hiemstra CA, Marquet RL, IJzermans JN. Extracorporeal perfusion for the treatment of acute liver failure. Ann. Surg. 2000; 231: 460-70.
44. Abouna GM, Boehmig HG, Serrou B, Amemiya H, Martineau G. Long-term hepatic support by intermittent multi-species liver perfusions. Lancet 1970; 2: 391-6.
45. Rozga J, Holzman MD, Ro MS et al Development of a hybrid bioartificial liver. Ann. Surg. 1993; 217: 502-11; discussion 509-11.
46. Kimoto S. The artificial liver. Experimental and clinical application. ASAIO Trans. 1959; 5: 102-12.
47. Burnell JM, Dawborn JK, Epstein RB et al. Acute hepatic coma treated by cross-circulation or exchange transfusion. N. Engl. J. Med. 1967; 276: 935-43.
48. Dixit V. Development of a bioartificial liver using isolated hepatocytes. Artif. Organs 1994; 18: 371-84.
49. Mito M, Ebata H, Kusano M, Onishi T, Saito T, Sakamoto S. Morphology and function of isolated hepatocytes transplanted into rat spleen. Transplantation 1979; 28: 499-505.
50. Ebata H, Kusano M, Onishi T, Saito T, Mito M. Liver regeneration utilizing isolated hepatocytes transplanted into the rat spleen. Surg. Forum 1978; 29: 338-40.
51. Rust C, Gores GJ. Hepatocyte transplantation in acute liver failure: a new therapeutic option for the next millennium? Liver Transpl. 2000; 6: 41-3.
52. Demetriou AA, Whiting J, Levenson SM et al. New method of hepatocyte transplantation and extracorporeal liver support. Ann. Surg. 1986; 204: 259-71.
53. Demetriou AA. Support of the acutely failing liver: state of the art. Ann. Surg. 1998; 228: 14-15.
54. Bilir BM, Guinette D, Karrer F et al. Hepatocyte transplantation in acute liver failure. Liver Transpl. 2000; 6: 32-40.
55. Arnaout WS, Moscioni AD, Barbour RL, Demetriou AA. Development of bioartificial liver: bilirubin conjugation in Gunn rats. J. Surg. Res. 1990; 48: 379-82.
56. Dixit V, Arthur M, Gitnick G. A morphological and functional evaluation of transplanted isolated encapsulated hepatocytes following long-term transplantation in Gunn rats. Biomater. Artif. Cells Immobilization Biotechnol. 1993; 21: 119-33.
57. Tsiaoussis J, Newsome PN, Nelson LJ, Hayes PC, Plevris JN. Which hepatocyte will it be? Hepatocyte choice for bioartificial liver support systems. Liver Transpl. 2001; 7: 2-10.
58. Spray DC, Fujita M, Saez JC et al. Proteoglycans and glycosaminoglycans induce gap junction synthesis and function in primary liver cultures. J. Cell Biol. 1987; 105: 541-51.
59. Reid LM, Jefferson DM. Culturing hepatocytes and other differentiated cells. Hepatology 1984; 4: 548-59.
60. Matsumura KN, Guevara GR, Huston H et al. Hybrid bioartificial liver in hepatic failure: preliminary clinical report. Surgery 1987; 101: 99-103.
61. Margulis MS, Erukhimov EA, Andreiman LA, Viksna LM. Temporary organ substitution by hemoperfusion through suspension of active donor hepatocytes in a total complex of intensive therapy in patients with acute hepatic insufficiency. Resuscitation 1989; 18: 85-94.
62. Barnes D, Sato G. Methods for growth of cultured cells in serum-free medium. Anal Biochem. 1980; 102: 255-70.
63. Koch KS, Lu XP, Brenner DA, Fey GH, Martinez-Conde A, Leffert HL. Mitogens and hepatocyte growth control in vivo and in vitro. In Vitro Cell Dev. Biol. 1990; 26: 1011-23.
64. Bucher NL, Robinson GS, Farmer SR. Effects of extracellular matrix on hepatocyte growth and gene expression: implications for hepatic regeneration and the repair of liver injury. Semin. Liver Dis. 1990; 10: 11-19.
65. Naik S, Santangini H, Gann K, Jauregui H. Influence of different substrates in detoxification activity of adult rat hepatocytes in long-term culture: implications for transplantation. Cell Transplant 1992; 1: 61-9.
66. Gerlach JC, Kloppel K, Muller C, Schnoy N, Smith MD, Neuhaus P. Hepatocyte aggregate culture technique for bioreactors in hybrid liver support systems. Int. J. Artif. Organs 1993; 16: 843-6.
67. Bader A, Knop E, Kern A et al. 3-D coculture of hepatic sinusoidal cells with primary hepatocytes - design of an organotypical model. Exp. Cell Res. 1996; 226: 223-33.
68. Obermayer N, Busse B, Grunwald A et al. Biochemical characterization of bioreactors for hybrid liver support: serum-free liver cell coculture of nonparenchymal and parenchymal cells. Transplant Proc. 2001; 33: 1930-1.
69. Mayer J, Karamuk E, Akaike T, Wintermantel E. Matrices for tissue engineering-scaffold structure for a bioartificial liver support system. J. Control. Release 2000; 64: 81-90.
70. Morsiani E, Pazzi P, Puviani AC et al. Early experiences with a porcine hepatocyte-based bioartificial liver in acute hepatic failure patients. Int. J. Artif. Organs 2002; 25: 192-202.
71. Uchino J, Tsuburaya T, Kumagai F et al. A hybrid bioartificial liver composed of multiplated hepatocyte monolayers. ASAIO Trans. 1988; 34: 972-7.
72. Shnyra A, Bocharov A, Bochkova N, Spirov V. Bioartificial liver using hepatocytes on biosilon microcarriers: treatment of chemically induced acute hepatic failure in rats. Artif. Organs 1991; 15: 189-97.
73. Nakazawa K, Ijima H, Fukuda J et al. Development of a hybrid artificial liver using polyurethane foam/hepatocyte spheroid culture in a preclinical pig experiment. Int. J. Artif. Organs 2002; 25: 51-60.
74. Karamuk E, Mayer J, Wintermantel E, Akaike T. Partially degradable film/fabric composites: textile scaffolds for liver cell culture. Artif. Organs 1999; 23: 881-4.
75. Selden C, Shariat A, McCloskey P, Ryder T, Roberts E, Hodgson H. Three-dimensional in vitro cell culture leads to a marked upregulation of cell function in human hepatocyte cell lines - an important tool for the development of a bioartificial liver machine. Ann. N. Y. Acad. Sci. 1999; 875: 353-63.
76. Rozga J, Podesta L, LePage E et al. A bioartificial liver to treat severe acute liver failure. Ann. Surg. 1994; 219: 538-44; discussion 544-6.
77. Watanabe FD, Mullon CJ, Hewitt WR et al. Clinical experience with a bioartificial liver in the treatment of severe liver failure. A phase I clinical trial. Ann. Surg. 1997; 225: 484-94.
78. Demetriou AA, Watanabe F, Rozga J. Artificial hepatic support systems. Prog. Liver Dis. 1995; 13: 331-48.
79. Nyberg SL, Platt JL, Shirabe K, Payne WD, Hu WS, Cerra FB. Immunoprotection of xenocytes in a hollow fiber bioartificial liver. Asaio J. 1992; 38: M463-7.
80. Wolf CF, Munkelt BE. Bilirubin conjugation by an artificial liver composed of cultured cells and synthetic capillaries. Trans. Am. Soc. Artif. Intern. Organs 1975; 21: 16-27.
81. Dixit V, Gitnick G. The bioartificial liver: state-of-the-art. Eur. J. Surg. Suppl 1998; 30: 71-6.
82. Flendrig LM, la Soe JW, Joining GG et al. In vitro evaluation of a novel bioreactor based on an integral oxygenator and a spirally wound nonwoven polyester matrix for hepatocyte culture as small aggregates. J. Hepatol. 1997; 26: 1379-92.
83. Sussman NL, Kelly JH. Artificial liver support. Clin. Invest Med. 1996; 19: 393-9.
84. Riordan SM, Williams R. Extracorporeal support and hepatocyte transplantation in acute liver failure and cirrhosis. J. Gastroenterol. Hepatol. 1999; 14: 757-70.
85. Nyberg SL, Remmel RP, Mann HJ, Peshwa MV, Hu WS, Cerra FB. Primary hepatocytes outperform Hep G2 cells as the source of biotransformation functions in a bioartificial liver. Ann. Surg. 1994; 220: 59-67.
86. Rozga J, Demetriou AA, Artificial liver. Evolution and future perspectives. Asaio J. 1995; 41: 831-7.
87. Jauregui HO. The technology of biological extracorporeal liver assist devices: from infancy to adolescence. Artif. Organs 1997; 21: 1163-8.
88. Werner A, Duvar S, Muthing J et al. Cultivation and characterization of a new immortalized human hepatocyte cell line, HepZ, for use in an artificial liver support system. Ann. N. Y. Acad. Sci. 1999; 875: 364-8.
89. Kobayashi N, Noguchi H, Watanabe T et al. A tightly regulated immortalized human fetal hepatocyte cell line to develop a bioartificial liver. Transplant. Proc. 2001; 33: 1948-9.
90. Kuddus R, Patzer JF 2nd, Lopez R et al. Clinical and laboratory evaluation of the safety of a bioartificial liver assist device for potential transmission of porcine endogenous retrovirus. Transplantation 2002; 73: 420-9.
91. Jauregui HO. Hepatocyte cell lines as the biological component of liver support. Artif. Organs 2001; 25: 509-12.
92. Hui T, Rozga J, Demetriou AA. Bioartificial liver support. J. Hepatobiliary Pancreat. Surg. 2001; 8: 1-15.
93. Gerlach J, Ziemer R, Neuhaus P. Fulminant liver failure: relevance of extracorporeal hybrid liver support systems. Int. J. Artif. Organs 1996; 19: 7-13.
94. Stevens C, Busuttil RW, Han S et al. An interim analysis of a phase II/III prospective randomized, multicentre, controlled trial of the HepatAssist bioartificial liver support system for the treatment of fulminant hepatic failure [Abstract]. Hepatology 2001; 34: 299A.
95. Ellis AJ, Hughes RD, Wendon JA et al. Pilot-controlled trial of the extracorporeal liver assist device in acute liver failure. Hepatology 1996; 24: 1446-51.
96. Mazariegos GV, Kramer DJ, Lopez RC et al. Safety observations in phase I clinical evaluation of the Excorp Medical Bioartificial Liver Support System after the first four patients. ASAIO J. 2001; 47: 471-5.
97. Sauer IM, Gerlach JC. Modular extracorporeal liver support. Artif. Organs 2002; 26: 703-33.
98. van de Kerkhove M, Di Florio E, Scuderi E, Mancini A, Cause F, Chamuleau RA. Clinical application of the AMC-Bioartificial liver. Gut 2001; 49: 1203.
99. Allen JW, Hassanein T, Bhatia SN. Advances in bioartificial liver devices. Hepatology 2001; 34: 447-55.
100. Suh KS, Lilja H, Kamohara Y et al. Bioartificial liver treatment in rats with fulminant hepatic failure: effect on DNA-binding activity of liver-enriched and growth-associated transcription factors. J. Surg. Res. 1999; 85: 243-50.
101. Miwa Y, Ellis AJ, Hughes RD, Langley PG, Wendon JA, Williams R. Effect of ELAD liver support on plasma HGF and TGF-beta 1 in acute liver failure. Int. J. Artif. Organs 1996; 19: 240-4.
102. Bhatia SN, Balis UJ, Yarmush ML, Toner M. Effect of cell-cell interactions in preservation of cellular phenotype: cocultivation of hepatocytes and nonparenchymal cells. Faseb. J. 1999; 13: 1883-900.
103. Kim SS, Utsunomiya H, Koski JA et al. Survival and function of hepatocytes on a novel three-dimensional synthetic biodegradable polymer scaffold with an intrinsic network of channels. Ann. Surg. 1998; 228: 8-13.
104. Flendrig LM, Maas MA, Daalhuisen J et al. Does the extend of the culture time of primary hepatocytes in a bioreactor affect the treatment efficacy of a bioartificial liver? Int. J. Artif. Organs 1998; 21: 542-7.
105. Sielaff TD, Nyberg SL, Rollins MD et al. Characterization of the three-compartment gel-entrapment porcine hepatocyte bioartificial liver. Cell Biol. Toxicol. 1997; 13: 357-64.
106. Yarmush ML, Dunn JC, Tompkins RG. Assessment of artificial liver support technology. Cell Transplant. 1992; 1: 323-41.